Literature DB >> 6450726

A low molecular weight inhibitor of the alternative complement pathway. I. Its isolation from human urine and the reaction mechanism.

K Nagaki, M Matsumoto, H Kitamura.   

Abstract

A low molecular inhibitor (LMW-INH) of the alternative pathway activation was isolated form healthy human urine. Its molecular weight was slightly higher than 1000. LMW-INH inhibited C3 convertase formation in fluid phase, on sheep erythrocytes and on zymosan particles. In contrast with beta 1H globulin LMW-INH showed no effect on the C3b binding site for B, and it inhibited the activation of CVF.B complex by D only when LMW-INH was simultaneously present with D. These results indicate that the reaction mechanism of LMW-INH is different from that of beta 1H globulin.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6450726      PMCID: PMC1458303     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  16 in total

1.  Isolation and properties of a glycine-rich beta-glycoprotein of human serum.

Authors:  T Boenisch; C A Alper
Journal:  Biochim Biophys Acta       Date:  1970-12-22

2.  Cleavage products of C4b produced by enzymes in human serum.

Authors:  S Shiraishi; R M Stroud
Journal:  Immunochemistry       Date:  1975-12

3.  The inactivator of the first component of human complement (C1INA). The complex formation with the activated first component of human complement (C1) or with its subcomponents.

Authors:  K Nagaki; K Iida; S Inai
Journal:  Int Arch Allergy Appl Immunol       Date:  1974

4.  C3b inactivator of man. 3. Further purification and production of antibody to C3b INA.

Authors:  S Ruddy; L G Hunsicker; K F Austen
Journal:  J Immunol       Date:  1972-03       Impact factor: 5.422

5.  Two anticomplementary factors in cobra venom: hemolysis of guinea pig erythrocytes by one of them.

Authors:  M Ballow; C G Cochrane
Journal:  J Immunol       Date:  1969-11       Impact factor: 5.422

6.  Trypsin-activated complex of human factor B with cobra venom factor (CVF), cleaving C3 and C5 and generating a lytic factor for unsensitized guinea pig erythrocytes. II. Physico-chemical characterization of the activated complex.

Authors:  A Miyama; T Kato; J Yokoo; S Kashiba
Journal:  Biken J       Date:  1975-12

7.  The reaction mechanism of human C5 in immune hemolysis.

Authors:  N R Cooper; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1970-10-01       Impact factor: 14.307

8.  Third component of human complement: purification from plasma and physicochemical characterization.

Authors:  B D Tack; J W Prahl
Journal:  Biochemistry       Date:  1976-10-05       Impact factor: 3.162

9.  Control of the amplification convertase of complement by the plasma protein beta1H.

Authors:  J M Weiler; M R Daha; K F Austen; D T Fearon
Journal:  Proc Natl Acad Sci U S A       Date:  1976-09       Impact factor: 11.205

10.  Modulation of the alternative complement pathways by beta 1 H globulin.

Authors:  K Whaley; S Ruddy
Journal:  J Exp Med       Date:  1976-11-02       Impact factor: 14.307

View more
  2 in total

1.  Characterization of alternative pathway inhibition by a serum derived, low molecular weight complement inhibitor.

Authors:  P J Baker; C J Parker; S G Osofsky
Journal:  Clin Exp Immunol       Date:  1984-01       Impact factor: 4.330

2.  Study on C3-like factor in the serum of a C3-deficient subject.

Authors:  H Kitamura; H Nishimukai; Y Sano; K Nagaki
Journal:  Immunology       Date:  1984-02       Impact factor: 7.397

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.